Pharmacy-managed program for providing education and discharge instructions for patients with heart failure

American Journal of Health-System Pharmacy

Volumn 71, Issue 2, 2014, Pages 134-139

  Warden, Bruce A ^a   Freels, Jessica Pryor ^a   Furuno, Jon P ^b   Mackay, John ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; CARDIOVASCULAR AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; HEALTH PROGRAM; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MALE; MEDICATION THERAPY MANAGEMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PHARMACIST; PHARMACY MANAGED PROGRAM; PRESCRIPTION; QUASI EXPERIMENTAL STUDY; SYSTOLIC HEART FAILURE; ACCREDITATION; ADOLESCENT; DOCUMENTATION; HOSPITAL PHARMACY; METHODOLOGY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PRACTICE GUIDELINE; SOCIOECONOMICS; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; DOCUMENTATION; FEMALE; GUIDELINE ADHERENCE; HEART FAILURE; HUMANS; JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS; MALE; MEDICATION RECONCILIATION; MIDDLE AGED; PATIENT CARE TEAM; PATIENT DISCHARGE; PATIENT EDUCATION AS TOPIC; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84906074090     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130103     Document Type: Article

References (35)

1. Roger VL, Go SA, Lloyd-Jones DM et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012; 125:e2-220.
2. Gattis WA, Hasselbald V, Whellan DJ et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team. Arch Intern Med. 1999; 159:1939-45.
3. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009; 360:1418-28.
4. U.S. Department of Health and Human Services. Hospital Compare. www.hospitalcompare.hhs.gov (accessed 2011 Dec 15).
5. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010; 121:e46-215.
6. Bonow RO. Measuring quality in heart failure: do we have the metrics? Circulation. 2008; 1:9-11.
7. Halasymani L, Kripalani S, Coleman E et al. Transition of care for hospitalized elderly patients - development of a discharge checklist for hospitalists. J Hosp Med. 2006; 1:354-60.
8. Walker PC, Tucker Jones JN, Mason NA. An advanced pharmacy practice experience in transitional care. Am J Pharm Educ. 2010; 74:20.
9. Murphy EM, Oxencis CR, Klauck JA et al. Medication reconciliation at an academic medical center: implementation of a comprehensive program from admission to discharge. Am J Health-Syst Pharm. 2009; 66:2126-31.
10. Walker PC, Bernstein SJ, Tucker Jones JN et al. Impact of a pharmacist-facilitated hospital discharge program. Arch Intern Med. 2009; 169:2003-10.
11. Varkey P, Cunningham J, O'Meara J et al. Multidisciplinary approach to inpatient medication reconciliation in an academic setting. Am J Health-Syst Pharm. 2007; 64:850-4.
12. Schnipper JL, Kirwin JL, Cotugno MC et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006; 166:565-71.
13. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: monitoring and patient education - 2009. Am J Health-Syst Pharm. 2010; 67:542-58.
14. Jack BW, Chetty VK, Anthony D et al. A reengineered hospital discharge program to decrease rehospitalization. Ann Intern Med. 2009; 150:178-88.
15. Al-Rashed SA, Wright DJ, Roebuck N et al. The value of inpatient pharmaceutical counseling to elderly patients prior to discharge. Br J Clin Pharmacol. 2002; 54:657-64.
16. Koehler BE, Richter KM, Youngblood L. Reduction of 30-day postdischarge hospital re-admission or emergency department (ED) visit rates in high-risk elderly medical patients through delivery of a targeted care bundle. J Hosp Med. 2009; 4:211-8.
17. Scullin C, Scott MG, Hogg A et al. An innovative approach to integrated medicines management. J Eval Clin Pract. 2007; 13:781-8.
18. Dudas V, Bookwalter T, Kerr KM et al. The impact of follow-up telephone calls to patients after hospitalization. Am J Med. 2001; 111:26S-30S.
19. Lopez-Cabezas C, Salvador CF, Quadrada DC et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs. regular follow-up in patients with heart failure. Farm Hosp. 2006; 30: 328-42.
20. Thompson CA. Integrated pharmacy practice helps reduce heart failure readmission rate. Am J Health-Syst Pharm. 2012; 69:1540-1. News.
21. Rainville EC. Impact of pharmacist interventions on hospital readmissions for heart failure. Am J Health-Syst Pharm. 1999; 56:1339-42.
22. Joint Commission. Specifications manual for national hospital inpatient quality measures. www.jointcommission.org/specifications-manual-for-national-hospital-inpatient-quality-measures.aspx (accessed 2013 Jan 8).
23. University HealthSystem Consortium. UHC hospital quality measures report. Oregon Health & Science University. Q110-Q410 data. www.uhc.edu (accessed 2011 Mar 10).
24. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685-91.
25. AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342:821-8.
26. Pfeffer MA, Braunwald E, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992; 327:669-77.
27. Kober L, Torp-Pedersen C, Carslen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995; 333:1670-6.
28. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345:1667-75.
29. Young JB, Dunlap ME, Pfeffer MA et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004; 110:2618-26.
30. Hjalmarson A, Fagerber B. MERIT-HF mortality and morbidity data. Basic Res Cardiol. 2000; 95(suppl 1):I98-103.
31. Waagstein F, Bristow MR, Swedberg K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993; 324:1441-6.
32. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996; 334: 1334-55.
33. Fowler MB. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial: carvedilol in severe heart failure. Am J Cardiol. 2004; 93(suppl):35B-39B.
34. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994; 90:1765-73.
35. Hertig J. Practitioners and the Pharmacy Practice Model Initiative: our opportunity to define the future. Am J Health-Syst Pharm. 2011; 68:1074-6.